Lung Cancer Screening Does Not Increase Unnecessary Surgery Rates
the ONA take:
Lung cancer screening programs result in a low incidence of surgical intervention for non-lung cancer diagnoses and a rare incidence of surgical intervention for benign disease, a new study published in the journal The Annals of Thoracic Surgery has shown.
For the study, researchers at Lahey Hospital & Medical Center retrospectively analyzed the surgical outcomes of 25 of the 1,654 patients who underwent low-dose computer tomography lung cancer screening.
Results showed that of the 25 that underwent surgery, five had non-lung cancer diagnoses, equating to an incidence of surgery for non-lung cancer diagnosis of 0.30%.
Researchers found that the incidence of surgery for benign disease was 0.24%. The other 20 patients had lung cancer, of which 18 had early stage disease and two had late stage disease.
“Lung cancer screening saves lives, and our study serves as a model for how to set up a screening program that is safe and effective for patients,” said Christina Williamson, MD, from Lahey Hospital & Medical Center.
“It is only by minimizing the number of operations for benign disease and maintaining a low morbidity and mortality for surgical resection that the full benefit of lung cancer screening can be realized in its widespread adoption in clinical practice,” Williamson said.
Lung cancer screening programs result in a low incidence of surgical intervention for non-lung cancer diagnoses.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|